Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
https://doi.org/10.17650/2222-1468-2024-14-4-42-50
Abstract
The article provides the latest data of our foreign colleagues on the potential use and dosing regimen of lenvatinib in real clinical practice. Since adverse events during lenvatinib treatment often lead to dose reduction or its discontinuation and, as a consequence, to a decrease in progression-free survival and overall survival benefit, optimization of lenvatinib dosing regimen is of great interest to experts from different countries. Today, so-called drug holidays are being actively studied as a possible option to reduce lenvatinib toxicity, without loss of efficacy in patients with advanced radioiodine-refractory differentiated thyroid cancer. In addition, given the small number of therapeutic options for this patient group, their low efficacy and poor availability of tumor mutation profiling and effect on target genes, a question arises: “Is it possible to benefit in progression-free survival and overall survival with lenvatinib rechallenge after disease progression in the 2nd or 3rd treatment lines?”
Keywords
About the Authors
E. V. BorodavinaRussian Federation
Ekaterina Vladimirovna Borodavina
4 Koroleva St., Obninsk 249036
S. I. Kutukova
Russian Federation
56 Prospekt Veteranov, Saint Petersburg 192288
6–8 L’va Tolstogo St., Saint Petersburg 197022
A. Yu. Shurinov
Russian Federation
4 Koroleva St., Obninsk 249036
V. V. Krylov
Russian Federation
4 Koroleva St., Obninsk 249036
References
1. Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: Unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7(5):541–54. DOI: 10.1586/eem.12.36
2. Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI: 10.1016/S0140-6736(13)60109-9
3. Cabanillas M.E., Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2019;9(4):49–61. (In Russ.). DOI: 10.17650/2222-1468-2019-9-4-49-61
4. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838
5. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470
6. Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6):699–704. DOI: 10.1530/ERC-18-0049
7. Borodavina E.V., Isaev P.A., Shurinov A.Yu. et al. Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation. Opukholi golovy i shei = Head and Neck Tumors 2020;10(1):65–72. (In Russ.). DOI: 10.17650/2222-1468-2020-10-1-65-72
8. Locati L.D., Piovesan A., Durante C. et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019;118:35–40. DOI: 10.1016/j.ejca.2019.05.031
9. Takahashi S., Tahara M., Ito K. et al. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 2020;37(9):3850–62. DOI: 10.1007/s12325-020-01433-8
10. Kish J.K., Chatterjee D., Wan Y. et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. Adv Ther 2020;37(6):2841–52. DOI: 10.1007/s12325-020-01362-6
11. Song E., Kim M., Kim E.Y. et al. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 2020;30(5):732–8. DOI: 10.1089/thy.2019.0476
12. Rumyantsev P.O., Borodavina E.V., Kutukova S.I., Vasilyeva E.B. Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice. Opukholi golovy i shei = Head and Neck Tumors 2021;11(3):47–55. (In Russ.). DOI: 10.17650/2222-1468-2021-11-3-47-55
13. Matsuyama C., Enokida T., Ueda Y. et al. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023;13:1139659. DOI: 10.3389/fonc.2023.1139659
14. Tahara M., Takami H., Ito Y. et al. A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 2024;34(5):566–74. DOI: 10.1089/thy.2023.0553
15. Mikoshiba T., Sekimizu M., Kono T. et al. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine 2024;85(2):777–85. DOI: 10.1007/s12020-024-03744-0
16. Felicetti F., Nervo A., Piovesan A. et al. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther 2017;17(12):1093–8. DOI: 10.1080/14737140.2017.1390432
17. Marotta V., Colao A., Faggiano A. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine 2015;50(3):824–5. DOI: 10.1007/s12020-015-0570-5
18. Takinami M., Yokota T. Rechallenge with lenvatinib after refractoriness to initial lenvatinib followed by sorafenib in a patient with metastatic papillary thyroid carcinoma. Case Rep Oncol 2020;13(2):522–7. DOI: 10.1159/000507344
19. Yokota T., Hamauchi S., Kawakami T., Fushiki K. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 2024;42(4):361–8. DOI: 10.1007/s10637-024-01449-9
20. Guo R., Chen X., Wang T. et al. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 2011;11:90. DOI: 10.1186/1471-2407-11-90
21. Becker A., Crombag L., Heideman D.A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47(17):2603–6. DOI: 10.1016/j.ejca.2011.06.046
22. Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid Cancer. J Clin Endocrinol Metab 2022;107(3):776–87. DOI: 10.1210/clinem/dgab731
23. Yu J., Liu Z., Su Y. et al. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2024;100(4):379–88. DOI: 10.1111/cen.15027
Review
For citations:
Borodavina E.V., Kutukova S.I., Shurinov A.Yu., Krylov V.V. Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? Head and Neck Tumors (HNT). 2024;14(4):42-50. (In Russ.) https://doi.org/10.17650/2222-1468-2024-14-4-42-50